Abstract:Abstract Background: Emerging evidence has shown that genetic factors can interact with host factors to influence patient's clinical outcomes. Inflammatory biomarkers have been identified as prognostic factors independent of tumor stage. To test the hypothesis that genetic variants in inflammation-related genes may modulate clinical outcome in non-small cell lung cancer (NSCLC) patients, we conducted a three-stage study, including an initial discovery phase and two validation phases. Methods: In the discovery phase, we analyzed the association between 19,458 SNPs in inflammation-related genes and SNPs from GWAS risk analysis, and clinical outcomes in 1,408 NSCLC patients. In the validation phases, the significant SNPs (p<0.05) were first validated in an additional 1,104 NSCLC patients from MD Anderson and then validated in 978 NSCLC patients from Harvard University. Meta-analysis was used to summarize the combined effect of each SNP in all three stages. Results: A total of 16 SNPs were identified as top candidate predictors of respective outcomes after showing consistent associations in all three stages. Among them, 5 SNPs were associated with overall survival in the entire populations. The most significant SNP is located on chromosome 6 (discovery: HR=1.49, 95%CI=1.10-2.01, P=0.010; combined validation: HR=1.45, 95%CI=1.17-1.78, P=0.001; all combined: HR=1.46, 95% CI=1.23-1.73, P=1.59×10-5). Five SNPs were associated with overall survival in late stage unresectable patients receiving chemotherapy. The most significant SNP, located on chromosome 13, consistently showed increased risk of death in all three phases (discovery: HR=1.40, 95%CI=1.09-1.81, P=0.010; combined validation: HR=1.36, 95%CI=1.14-1.63, P=0.001; all combined: HR=1.37, 95% CI=1.19-1.59, P=2.26×10-5). Six SNPs were consistently associated with progression in early stage patient receiving surgery only. The top SNP was on chromosome 1 with protective effect against developing progression in all three phases (discovery: HR=0.52, 95%CI=0.32-0.86, P=0.033; combined validation: HR=0.63, 95%CI=0.49-0.82, P=0.001; all combined: HR=0.62, 95% CI=0.5-0.79, P=5.47×10-5). To our knowledge, this is the first study to systematically evaluate the association of genetic variations in major inflammation genes and NSCLC patients’ clinical outcomes with a multi-stage design using two of the largest lung studies in the US. Our study provides evidence that genetic variations in inflammation genes may affect clinical outcomes in NSCLC patients. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4662. doi:10.1158/1538-7445.AM2011-4662

No Association Between Genetic Variants in Angiogenesis and Inflammation Pathway Genes and Breast Cancer Survival among Chinese Women

Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer.

Common Genetic Variants Related to Vitamin D Status Are Not Associated with Esophageal Squamous Cell Carcinoma Risk in China.

Abstract 4843: Genetic Variants in Notch Signaling Pathway and Ovarian Cancer.

Genetic Variants in the Hedgehog Signaling Pathway Genes Are Associated with Gastric Cancer Risk in a Chinese Han Population

The Association of CASC16 Variants with Breast Cancer Risk in a Northwest Chinese Female Population

Abstract 4662: Genetic Predictors of Clinical Outcomes for Patients with Non-Small Cell Lung Cancer

Genetic Polymorphism in a VEGF-Independent Angiogenesis Gene ANGPT1 and Overall Survival of Colorectal Cancer Patients after Surgical Resection

Association of Genetic Markers in the BCL-2 Family of Apoptosis-Related Genes with Endometrial Cancer Risk in a Chinese Population

Association Between 15 Known or Potential Breast Cancer Susceptibility Genes and Breast Cancer Risks in Chinese Women

Inflammation-related genetic variations and survival in patients with advanced non-small cell lung cancer receiving first-line chemotherapy.

Genetic Variations In Apoptosis Pathway Are Associated With Survival In Late Stage Non-Small Cell Lung Cancer

Genetic variants in telomere-maintenance genes are associated with ovarian cancer risk and outcome

Association of Germline Variation in Ccne1 and Cdk2 with Breast Cancer Risk, Progression and Survival among Chinese Han Women

Abstract 894: Genetic Variations in the Angiogenesis Pathway Modulate Clinical Outcomes of Bladder Cancer

Breast cancer association studies in a Han Chinese population using 10 European-ancestry-associated breast cancer susceptibility SNPs

The impact of Angiopoietin-2 genetic polymorphisms on susceptibility for malignant breast neoplasms

Association Study of Germline Variants in CCNB1 and CDK1 with Breast Cancer Susceptibility, Progression, and Survival among Chinese Han Women

Variants in Notch Signalling Pathway Genes, PSEN1 and MAML2, Predict Overall Survival in Chinese Patients with Epithelial Ovarian Cancer.

Association of Genetic Polymorphisms in CDH1 and CTNNB1 with Breast Cancer Susceptibility and Patients' Prognosis among Chinese Han Women.

Prognostic Significance of Differential Expression of Angiogenic Genes in Women with High-Grade Serous Ovarian Carcinoma